Tesaro (Nasdaq: TSRO) is launching a managed access program in the USA for its investigational oncology treatment niraparib.
The scheme, which is also known as an expanded access program (EAP), is being administered by British pharmaceuticals and services firm Clinigen Group (AIM: CLIN).
EAP programs allow patients with life-threatening conditions to access late-stage investigational drugs, before they have received regulatory approval. They can also help guide future development of a therapy, through anecdotal evidence of its effects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze